Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Publication year range
1.
Acta Paediatr ; 101(9): e426-30, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22568565

ABSTRACT

AIM: To report our 10 year experience with noradrenaline use in children with septic shock focusing on doses, routes of administration and complications. METHODS: Retrospective single-centre review of children with septic shock who received noradrenaline between 2000 and 2010. RESULTS: We identified 144 children with septic shock treated with noradrenaline, in 22% as the first-line drug. The median volume resuscitation before vasoactive agent administration was 50 mL/kg interquartile range [IQR: 30-70]. Mean doses of noradrenaline ranged from 0.5 ± 0.4 µg/kg per min (starting dose) to 2.5 ± 2.2 µg/kg per min (maximum dose). Noradrenaline was administered via peripheral venous access or intra-osseous route in 19% of cases for a median duration of 3 h [IQR: 2-4] without any adverse effects. The use of noradrenaline increased over the study period. Mortality rate was 45% with a significant decrease over the study period. Adverse effects included arrhythmia in two children and hypertension in eight children. None of these arrhythmias required treatment and hypertension resolved with the noradrenaline dose reduction. CONCLUSION: Higher doses of noradrenaline than those suggested in the literature may be necessary to reverse hypotension and hypoperfusion. The use of noradrenaline through peripheral venous access or intra-osseous route was safe, without any adverse effects.


Subject(s)
Norepinephrine/administration & dosage , Norepinephrine/adverse effects , Shock, Septic/drug therapy , Vasoconstrictor Agents/administration & dosage , Vasoconstrictor Agents/adverse effects , Bacteremia/complications , Child , Child, Preschool , Dobutamine/administration & dosage , Dopamine/administration & dosage , Dose-Response Relationship, Drug , Female , Gastrointestinal Diseases/complications , Humans , Infant , Male , Respiratory Tract Infections/complications , Retrospective Studies , Shock, Septic/etiology
2.
Rev Neurol (Paris) ; 166(6-7): 648-52, 2010.
Article in French | MEDLINE | ID: mdl-20171707

ABSTRACT

UNLABELLED: Morbidity and mortality are high in children with refractory status epilepticus (RSE). Here, we assess the efficacy of midazolam for RSE in children. METHODS: This was a retrospective analysis of 29 children admitted to the Lille University Hospital pediatric intensive care unit (PICU) for RSE between May 2006 and July 2008. The onset of the study corresponded with a new therapeutic protocol applied in the PICU for RSE where midazolam was proposed as the first-line treatment (bolus ten continuous infusion until control) to be replaced by thiopenthal in case of failure. RESULTS: We recorded 29 patients with RSE during the study period: 26 were treated with midazolam, including two where midazolam replaced thiopenthal because of hypotension. Midazolam successfully controlled RSE in 58% of patients. Mean delay to cessation of RSE was 48+/-65 minutes. Hypotension was observed in 8% of midazolam-treated patients and 71% of thiopenthal-treated patients. Overall mortality was 15% (4/26). Two deaths occurred long after the cessation of RSE. None of the deaths occurred in midazolam-treated patients. CONCLUSION: Midazolam is an efficient treatment for RSE in children. Morbidity and mortality appear to be lower with midazolam compared with other antiepileptic drugs used for the treatment of RSE.


Subject(s)
GABA Modulators/therapeutic use , Midazolam/therapeutic use , Status Epilepticus/drug therapy , Adolescent , Catecholamines/blood , Child , Child, Preschool , Female , GABA Modulators/adverse effects , Humans , Hypotension/chemically induced , Infant , Male , Midazolam/adverse effects , Patient Acceptance of Health Care , Retrospective Studies , Thiopental/therapeutic use
3.
J Biomed Mater Res ; 36(1): 99-108, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9212394

ABSTRACT

Cell adhesion and spreading of chick embryo vascular and corneal explants grown on rough and smooth poly (methyl methacrylate) (PMMA) were analyzed to test the cell response specificity to substratum surface properties. Different degrees of roughness were obtained by sand-blasting PMMA with alumina grains. Hydrophilic and hydrophobic components of the surface free energy (SFE) were calculated according to Good-van Oss's model. Contact angles were determined using a computerized angle meter. The apolar component of the SFE gamma s(LW), increased with a slight roughness whereas the basic component, gamma s-, decreased. The acido-basic properties disappeared as roughness increased. Incubation of PMMA in culture medium, performed to test the influence if the biological environment, allowed surface adsorption of medium proteins which annihilated roughness effect and restored hydrophilic properties. An organotypic culture assay was carried out in an attempt to relate the biocompatibility to substratum surface state. Cell migration was calculated from the area of cell layer. Cellular adhesion was determined by measuring the kinetic of release of enzymatically dissociated cells. A slight roughness raised the migration are to an upper extent no matter which cell type. Enhancement of the cell adhesion potential was related to the degree of roughness and the hydrophobicity.


Subject(s)
Biocompatible Materials , Cell Adhesion , Cell Movement , Methylmethacrylates , Animals , Aorta/ultrastructure , Chick Embryo , Cornea/ultrastructure , Extracellular Matrix/ultrastructure , Materials Testing , Microscopy, Electron, Scanning , Organ Culture Techniques , Surface Properties , Thermodynamics , Water
SELECTION OF CITATIONS
SEARCH DETAIL